Search

Your search keyword '"Bast, Robert C."' showing total 1,281 results
Start Over Author "Bast, Robert C."
1,281 results on '"Bast, Robert C."'

2. Amyloid-like p53 as prognostic biomarker in serous ovarian cancer—a study of the OVCAD consortium

Author

Heinzl, Nicole, Maritschnegg, Elisabeth, Koziel, Katarzyna, Schilhart-Wallisch, Christine, Heinze, Georg, Yang, Wei-Lei, Bast, Robert C., Sehouli, Jalid, Braicu, Elena I., Vergote, Ignace, Van Gorp, Toon, Mahner, Sven, Paspalj, Valentina, Grimm, Christoph, Obermayr, Eva, Schuster, Eva, Holzer, Barbara, Rousseau, Frederic, Schymkowitz, Joost, Concin, Nicole, and Zeillinger, Robert

Published
2023
Full Text
View/download PDF

5. In vivo modeling of metastatic human high-grade serous ovarian cancer in mice.

Author

Kim, Olga, Park, Eun Young, Klinkebiel, David L, Pack, Svetlana D, Shin, Yong-Hyun, Abdullaev, Zied, Emerson, Robert E, Coffey, Donna M, Kwon, Sun Young, Creighton, Chad J, Kwon, Sanghoon, Chang, Edmund C, Chiang, Theodore, Yatsenko, Alexander N, Chien, Jeremy, Cheon, Dong-Joo, Yang-Hartwich, Yang, Nakshatri, Harikrishna, Nephew, Kenneth P, Behringer, Richard R, Fernández, Facundo M, Cho, Chi-Heum, Vanderhyden, Barbara, Drapkin, Ronny, Bast, Robert C, Miller, Kathy D, Karpf, Adam R, and Kim, Jaeyeon

Subjects
Cell Line, Tumor, Animals, Mice, Knockout, Humans, Mice, Cystadenocarcinoma, Serous, Peritoneal Neoplasms, Ovarian Neoplasms, Neoplasm Metastasis, Disease Models, Animal, Chromosomal Instability, Ribonuclease III, Antineoplastic Agents, Drug Screening Assays, Antitumor, Feasibility Studies, DNA Repair, Drug Resistance, Neoplasm, Mutation, Female, Tumor Suppressor Protein p53, PTEN Phosphohydrolase, DEAD-box RNA Helicases, Primary Cell Culture, Neoplasm Grading, Developmental Biology, Genetics
Abstract

Metastasis is responsible for 90% of human cancer mortality, yet it remains a challenge to model human cancer metastasis in vivo. Here we describe mouse models of high-grade serous ovarian cancer, also known as high-grade serous carcinoma (HGSC), the most common and deadliest human ovarian cancer type. Mice genetically engineered to harbor Dicer1 and Pten inactivation and mutant p53 robustly replicate the peritoneal metastases of human HGSC with complete penetrance. Arising from the fallopian tube, tumors spread to the ovary and metastasize throughout the pelvic and peritoneal cavities, invariably inducing hemorrhagic ascites. Widespread and abundant peritoneal metastases ultimately cause mouse deaths (100%). Besides the phenotypic and histopathological similarities, mouse HGSCs also display marked chromosomal instability, impaired DNA repair, and chemosensitivity. Faithfully recapitulating the clinical metastases as well as molecular and genomic features of human HGSC, this murine model will be valuable for elucidating the mechanisms underlying the development and progression of metastatic ovarian cancer and also for evaluating potential therapies.

Published
2020

6. Analysis of RAS protein interactions in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders

Author

Li, Yao-Cheng, Lytle, Nikki K, Gammon, Seth T, Wang, Luke, Hayes, Tikvah K, Sutton, Margie N, Bast, Robert C, Der, Channing J, Piwnica-Worms, David, McCormick, Frank, and Wahl, Geoffrey M

Subjects
Cancer, Aetiology, 1.1 Normal biological development and functioning, Underpinning research, 2.1 Biological and endogenous factors, Autophagosomes, Cell Membrane, Humans, Lysosomes, Models, Molecular, Protein Interaction Domains and Motifs, Protein Isoforms, Signal Transduction, ras Proteins, KRAS, NRAS, HRAS, protein-protein interaction, split-luciferase complementation, protein–protein interaction
Abstract

HRAS, NRAS, and KRAS4A/KRAS4B comprise the RAS family of small GTPases that regulate signaling pathways controlling cell proliferation, differentiation, and survival. RAS pathway abnormalities cause developmental disorders and cancers. We found that KRAS4B colocalizes on the cell membrane with other RAS isoforms and a subset of prenylated small GTPase family members using a live-cell quantitative split luciferase complementation assay. RAS protein coclustering is mainly mediated by membrane association-facilitated interactions (MAFIs). Using the RAS-RBD (CRAF RAS binding domain) interaction as a model system, we showed that MAFI alone is not sufficient to induce RBD-mediated RAS inhibition. Surprisingly, we discovered that high-affinity membrane-targeted RAS binding proteins inhibit RAS activity and deplete RAS proteins through an autophagosome-lysosome-mediated degradation pathway. Our results provide a mechanism for regulating RAS activity and protein levels, a more detailed understanding of which should lead to therapeutic strategies for inhibiting and depleting oncogenic RAS proteins.

Published
2020

7. Targeting progesterone signaling prevents metastatic ovarian cancer

Author

Kim, Olga, Park, Eun Young, Kwon, Sun Young, Shin, Sojin, Emerson, Robert E., Shin, Yong-Hyun, DeMayo, Francesco J., Lydon, John P., Coffey, Donna M., Hawkins, Shannon M., Quilliam, Lawrence A., Cheon, Dong-Joo, Fernández, Facundo M., Nephew, Kenneth P., Karpf, Adam R., Widschwendter, Martin, Sood, Anil K., Bast, Robert C., Godwin, Andrew K., Miller, Kathy D., Cho, Chi-Heum, and Kim, Jaeyeon

Published
2020

9. Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer

Author

Young Han, Chae, primary, Bedia, Jacob S., additional, Yang, Wei-Lei, additional, Hawley, Sarah J., additional, Bergan, Lindsay, additional, Hopper, Marika, additional, Celestino, Joseph, additional, Guo, Jing, additional, Gornet, Terrie G., additional, Soosaipillai, Antoninus, additional, Yang, Hailing, additional, Doskocil, Samantha D., additional, Lokshin, Anna E., additional, Handy, Beverly C., additional, Diamandis, Eleftherios P., additional, Moore, Richard G., additional, Lu, Karen H., additional, Lu, Zhen, additional, Anderson, Karen S., additional, Drescher, Charles W., additional, Skates, Steven J., additional, and Bast, Robert C., additional

Published
2024
Full Text
View/download PDF

10. Normal Risk Ovarian Screening Study: 21-Year Update

Author

Han, Chae Young, primary, Lu, Karen H., additional, Corrigan, Gwen, additional, Perez, Alexandra, additional, Kohring, Sharlene D., additional, Celestino, Joseph, additional, Bedi, Deepak, additional, Bedia, Enrique, additional, Bevers, Therese, additional, Boruta, David, additional, Carlson, Matthew, additional, Holman, Laura, additional, Leeds, Leroy, additional, Mathews, Cara, additional, McCann, Georgia, additional, Moore, Richard G., additional, Schlumbrecht, Matthew, additional, Slomovitz, Brian, additional, Tobias, Dan, additional, Williams-Brown, Yvette, additional, Bevers, Michael W., additional, Liu, Jinsong, additional, Gornet, Terrie G., additional, Handy, Beverly C., additional, Lu, Zhen, additional, Bedia, Jacob S., additional, Skates, Steven J., additional, and Bast, Robert C., additional

Published
2024
Full Text
View/download PDF

13. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

Author

Bowtell, David D, Böhm, Steffen, Ahmed, Ahmed A, Aspuria, Paul-Joseph, Bast, Robert C, Beral, Valerie, Berek, Jonathan S, Birrer, Michael J, Blagden, Sarah, Bookman, Michael A, Brenton, James D, Chiappinelli, Katherine B, Martins, Filipe Correia, Coukos, George, Drapkin, Ronny, Edmondson, Richard, Fotopoulou, Christina, Gabra, Hani, Galon, Jérôme, Gourley, Charlie, Heong, Valerie, Huntsman, David G, Iwanicki, Marcin, Karlan, Beth Y, Kaye, Allyson, Lengyel, Ernst, Levine, Douglas A, Lu, Karen H, McNeish, Iain A, Menon, Usha, Narod, Steven A, Nelson, Brad H, Nephew, Kenneth P, Pharoah, Paul, Powell, Daniel J, Ramos, Pilar, Romero, Iris L, Scott, Clare L, Sood, Anil K, Stronach, Euan A, and Balkwill, Frances R

Subjects
Cancer, Ovarian Cancer, Prevention, Rare Diseases, Good Health and Well Being, Cystadenocarcinoma, Serous, Female, Humans, Neoplasm Grading, Ovarian Neoplasms, Prognosis, Survival Rate, Medical and Health Sciences, Oncology & Carcinogenesis
Abstract

High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015.

Published
2015

14. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Author

Tefferi, Ayalew, Kantarjian, Hagop, Rajkumar, S Vincent, Baker, Lawrence H, Abkowitz, Jan L, Adamson, John W, Advani, Ranjana Hira, Allison, James, Antman, Karen H, Bast, Robert C, Bennett, John M, Benz, Edward J, Berliner, Nancy, Bertino, Joseph, Bhatia, Ravi, Bhatia, Smita, Bhojwani, Deepa, Blanke, Charles D, Bloomfield, Clara D, Bosserman, Linda, Broxmeyer, Hal E, Byrd, John C, Cabanillas, Fernando, Canellos, George Peter, Chabner, Bruce A, Chanan-Khan, Asher, Cheson, Bruce, Clarkson, Bayard, Cohn, Susan L, Colon-Otero, Gerardo, Cortes, Jorge, Coutre, Steven, Cristofanilli, Massimo, Curran, Walter J, Daley, George Q, DeAngelo, Daniel J, Deeg, H Joachim, Einhorn, Lawrence H, Erba, Harry P, Esteva, Francisco J, Estey, Elihu, Fidler, Isaiah J, Foran, James, Forman, Stephen, Freireich, Emil, Fuchs, Charles, George, James N, Gertz, Morie A, Giralt, Sergio, Golomb, Harvey, Greenberg, Peter, Gutterman, Jordan, Handin, Robert I, Hellman, Samuel, Hoff, Paulo Marcelo, Hoffman, Ronald, Hong, Waun Ki, Horowitz, Mary, Hortobagyi, Gabriel N, Hudis, Clifford, Issa, Jean Pierre, Johnson, Bruce Evan, Kantoff, Philip W, Kaushansky, Kenneth, Khayat, David, Khuri, Fadlo R, Kipps, Thomas J, Kripke, Margaret, Kyle, Robert A, Larson, Richard A, Lawrence, Theodore S, Levine, Ross, Link, Michael P, Lippman, Scott M, Lonial, Sagar, Lyman, Gary H, Markman, Maurie, Mendelsohn, John, Meropol, Neal J, Messinger, Yoav, Mulvey, Therese M, O'Brien, Susan, Perez-Soler, Roman, Pollock, Raphael, Prchal, Josef, Press, Oliver, Radich, Jerald, Rai, Kanti, Rosenberg, Saul A, Rowe, Jacob M, Rugo, Hope, Runowicz, Carolyn D, Sandmaier, Brenda M, Saven, Alan, Schafer, Andrew I, Schiffer, Charles, Sekeres, Mikkael A, Silver, Richard T, Siu, Lillian L, and Steensma, David P

Subjects
Humans, Neoplasms, Antineoplastic Agents, Patient Advocacy, Patient Participation, Drug Costs, Prescription Fees, United States, Medical and Health Sciences
Published
2015

16. SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers

Author

Lu, Zhen, Mao, Weiqun, Yang, Hailing, Santiago-OFarrill, Janice M., Rask, Philip J., Mondal, Jayanta, Chen, Hu, Ivan, Cristina, Liu, Xiuping, Liu, Chang-Gong, Xi, Yuanxin, Masuda, Kenta, Carrami, Eli M., Chen, Meng, Tang, Yitao, Pang, Lan, Lakomy, David S., Calin, George A., Liang, Han, Ahmed, Ahmed A., Vankayalapati, Hariprasad, and Bast, Robert C., Jr.

Subjects
Drug synergism, Ovarian cancer -- Drug therapy -- Models, Health care industry
Abstract

Poly(ADP-ribose) polymerase inhibitors (PARP inhibitors) have had an increasing role in the treatment of ovarian and breast cancers. PARP inhibitors are selectively active in cells with homologous recombination DNA repair deficiency caused by mutations in BRCA1/2 and other DNA repair pathway genes. Cancers with homologous recombination DNA repair proficiency respond poorly to PARP inhibitors. Cancers that initially respond to PARP inhibitors eventually develop drug resistance. We have identified salt-inducible kinase 2 (SIK2) inhibitors, ARN3236 and ARN3261, which decreased DNA double-strand break (DSB) repair functions and produced synthetic lethality with multiple PARP inhibitors in both homologous recombination DNA repair deficiency and proficiency cancer cells. SIK2 is required for centrosome splitting and PI3K activation and regulates cancer cell proliferation, metastasis, and sensitivity to chemotherapy. Here, we showed that SIK2 inhibitors sensitized ovarian and triple-negative breast cancer (TNBC) cells and xenografts to PARP inhibitors. SIK2 inhibitors decreased PARP enzyme activity and phosphorylation of class-IIa histone deacetylases (HDAC4/5/7). Furthermore, SIK2 inhibitors abolished class-IIa HDAC4/5/7-associated transcriptional activity of myocyte enhancer factor-2D (MEF2D), decreasing MEF2D binding to regulatory regions with high chromatin accessibility in FANCD2, EXO1, and XRCC4 genes, resulting in repression of their functions in the DNA DSB repair pathway. The combination of PARP inhibitors and SIK2 inhibitors provides a therapeutic strategy to enhance PARP inhibitor sensitivity for ovarian cancer and TNBC., Introduction Recent studies indicate that DNA damage, aberrations in the DNA damage response, and defects in DNA repair machinery play a major role in ovarian cancer and triple-negative breast cancer [...]

Published
2022
Full Text
View/download PDF

19. Guidelines for the use and interpretation of assays for monitoring autophagy.

Author

Klionsky, Daniel J, Abdalla, Fabio C, Abeliovich, Hagai, Abraham, Robert T, Acevedo-Arozena, Abraham, Adeli, Khosrow, Agholme, Lotta, Agnello, Maria, Agostinis, Patrizia, Aguirre-Ghiso, Julio A, Ahn, Hyung Jun, Ait-Mohamed, Ouardia, Ait-Si-Ali, Slimane, Akematsu, Takahiko, Akira, Shizuo, Al-Younes, Hesham M, Al-Zeer, Munir A, Albert, Matthew L, Albin, Roger L, Alegre-Abarrategui, Javier, Aleo, Maria Francesca, Alirezaei, Mehrdad, Almasan, Alexandru, Almonte-Becerril, Maylin, Amano, Atsuo, Amaravadi, Ravi, Amarnath, Shoba, Amer, Amal O, Andrieu-Abadie, Nathalie, Anantharam, Vellareddy, Ann, David K, Anoopkumar-Dukie, Shailendra, Aoki, Hiroshi, Apostolova, Nadezda, Arancia, Giuseppe, Aris, John P, Asanuma, Katsuhiko, Asare, Nana YO, Ashida, Hisashi, Askanas, Valerie, Askew, David S, Auberger, Patrick, Baba, Misuzu, Backues, Steven K, Baehrecke, Eric H, Bahr, Ben A, Bai, Xue-Yuan, Bailly, Yannick, Baiocchi, Robert, Baldini, Giulia, Balduini, Walter, Ballabio, Andrea, Bamber, Bruce A, Bampton, Edward TW, Bánhegyi, Gábor, Bartholomew, Clinton R, Bassham, Diane C, Bast, Robert C, Batoko, Henri, Bay, Boon-Huat, Beau, Isabelle, Béchet, Daniel M, Begley, Thomas J, Behl, Christian, Behrends, Christian, Bekri, Soumeya, Bellaire, Bryan, Bendall, Linda J, Benetti, Luca, Berliocchi, Laura, Bernardi, Henri, Bernassola, Francesca, Besteiro, Sébastien, Bhatia-Kissova, Ingrid, Bi, Xiaoning, Biard-Piechaczyk, Martine, Blum, Janice S, Boise, Lawrence H, Bonaldo, Paolo, Boone, David L, Bornhauser, Beat C, Bortoluci, Karina R, Bossis, Ioannis, Bost, Frédéric, Bourquin, Jean-Pierre, Boya, Patricia, Boyer-Guittaut, Michaël, Bozhkov, Peter V, Brady, Nathan R, Brancolini, Claudio, Brech, Andreas, Brenman, Jay E, Brennand, Ana, Bresnick, Emery H, Brest, Patrick, Bridges, Dave, Bristol, Molly L, Brookes, Paul S, Brown, Eric J, and Brumell, John H

Subjects
Animals, Humans, Biological Assay, Models, Biological, Autophagy, Generic health relevance, autolysosome, autophagosome, flux, LC3, lysosome, phagophore, stress, vacuole, Biochemistry and Cell Biology, Biochemistry & Molecular Biology
Abstract

In 2008 we published the first set of guidelines for standardizing research in autophagy. Since then, research on this topic has continued to accelerate, and many new scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Accordingly, it is important to update these guidelines for monitoring autophagy in different organisms. Various reviews have described the range of assays that have been used for this purpose. Nevertheless, there continues to be confusion regarding acceptable methods to measure autophagy, especially in multicellular eukaryotes. A key point that needs to be emphasized is that there is a difference between measurements that monitor the numbers or volume of autophagic elements (e.g., autophagosomes or autolysosomes) at any stage of the autophagic process vs. those that measure flux through the autophagy pathway (i.e., the complete process); thus, a block in macroautophagy that results in autophagosome accumulation needs to be differentiated from stimuli that result in increased autophagic activity, defined as increased autophagy induction coupled with increased delivery to, and degradation within, lysosomes (in most higher eukaryotes and some protists such as Dictyostelium) or the vacuole (in plants and fungi). In other words, it is especially important that investigators new to the field understand that the appearance of more autophagosomes does not necessarily equate with more autophagy. In fact, in many cases, autophagosomes accumulate because of a block in trafficking to lysosomes without a concomitant change in autophagosome biogenesis, whereas an increase in autolysosomes may reflect a reduction in degradative activity. Here, we present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes. These guidelines are not meant to be a formulaic set of rules, because the appropriate assays depend in part on the question being asked and the system being used. In addition, we emphasize that no individual assay is guaranteed to be the most appropriate one in every situation, and we strongly recommend the use of multiple assays to monitor autophagy. In these guidelines, we consider these various methods of assessing autophagy and what information can, or cannot, be obtained from them. Finally, by discussing the merits and limits of particular autophagy assays, we hope to encourage technical innovation in the field.

Published
2012

23. Perspectives on This Article from Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens

Author

Cramer, Daniel W., primary, Bast, Robert C., primary, Berg, Christine D., primary, Diamandis, Eleftherios P., primary, Godwin, Andrew K., primary, Hartge, Patricia, primary, Lokshin, Anna E., primary, Lu, Karen H., primary, McIntosh, Martin W., primary, Mor, Gil, primary, Patriotis, Christos, primary, Pinsky, Paul F., primary, Thornquist, Mark D., primary, Scholler, Nathalie, primary, Skates, Steven J., primary, Sluss, Patrick M., primary, Srivastava, Sudhir, primary, Ward, David C., primary, Zhang, Zhen, primary, Zhu, Claire S., primary, and Urban, Nicole, primary

Published
2023
Full Text
View/download PDF

28. Data from A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer

Author

Zhu, Claire S., primary, Pinsky, Paul F., primary, Cramer, Daniel W., primary, Ransohoff, David F., primary, Hartge, Patricia, primary, Pfeiffer, Ruth M., primary, Urban, Nicole, primary, Mor, Gil, primary, Bast, Robert C., primary, Moore, Lee E., primary, Lokshin, Anna E., primary, McIntosh, Martin W., primary, Skates, Steven J., primary, Vitonis, Allison, primary, Zhang, Zhen, primary, Ward, David C., primary, Symanowski, James T., primary, Lomakin, Aleksey, primary, Fung, Eric T., primary, Sluss, Patrick M., primary, Scholler, Nathalie, primary, Lu, Karen H., primary, Marrangoni, Adele M., primary, Patriotis, Christos, primary, Srivastava, Sudhir, primary, Buys, Saundra S., primary, and Berg, Christine D., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Materials from A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer

Author

Zhu, Claire S., primary, Pinsky, Paul F., primary, Cramer, Daniel W., primary, Ransohoff, David F., primary, Hartge, Patricia, primary, Pfeiffer, Ruth M., primary, Urban, Nicole, primary, Mor, Gil, primary, Bast, Robert C., primary, Moore, Lee E., primary, Lokshin, Anna E., primary, McIntosh, Martin W., primary, Skates, Steven J., primary, Vitonis, Allison, primary, Zhang, Zhen, primary, Ward, David C., primary, Symanowski, James T., primary, Lomakin, Aleksey, primary, Fung, Eric T., primary, Sluss, Patrick M., primary, Scholler, Nathalie, primary, Lu, Karen H., primary, Marrangoni, Adele M., primary, Patriotis, Christos, primary, Srivastava, Sudhir, primary, Buys, Saundra S., primary, and Berg, Christine D., primary

Published
2023
Full Text
View/download PDF

41. Perspectives on This Article from A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer

Author

Zhu, Claire S., primary, Pinsky, Paul F., primary, Cramer, Daniel W., primary, Ransohoff, David F., primary, Hartge, Patricia, primary, Pfeiffer, Ruth M., primary, Urban, Nicole, primary, Mor, Gil, primary, Bast, Robert C., primary, Moore, Lee E., primary, Lokshin, Anna E., primary, McIntosh, Martin W., primary, Skates, Steven J., primary, Vitonis, Allison, primary, Zhang, Zhen, primary, Ward, David C., primary, Symanowski, James T., primary, Lomakin, Aleksey, primary, Fung, Eric T., primary, Sluss, Patrick M., primary, Scholler, Nathalie, primary, Lu, Karen H., primary, Marrangoni, Adele M., primary, Patriotis, Christos, primary, Srivastava, Sudhir, primary, Buys, Saundra S., primary, and Berg, Christine D., primary

Published
2023
Full Text
View/download PDF

43. Data from Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens

Author

Cramer, Daniel W., primary, Bast, Robert C., primary, Berg, Christine D., primary, Diamandis, Eleftherios P., primary, Godwin, Andrew K., primary, Hartge, Patricia, primary, Lokshin, Anna E., primary, Lu, Karen H., primary, McIntosh, Martin W., primary, Mor, Gil, primary, Patriotis, Christos, primary, Pinsky, Paul F., primary, Thornquist, Mark D., primary, Scholler, Nathalie, primary, Skates, Steven J., primary, Sluss, Patrick M., primary, Srivastava, Sudhir, primary, Ward, David C., primary, Zhang, Zhen, primary, Zhu, Claire S., primary, and Urban, Nicole, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Data from A Blood-Based Metabolite Panel for Distinguishing Ovarian Cancer from Benign Pelvic Masses

Author

Irajizad, Ehsan, primary, Han, Chae Y., primary, Celestino, Joseph, primary, Wu, Ranran, primary, Murage, Eunice, primary, Spencer, Rachelle, primary, Dennison, Jennifer B., primary, Vykoukal, Jody, primary, Long, James P., primary, Do, Kim Anh, primary, Drescher, Charles, primary, Lu, Karen, primary, Lu, Zhen, primary, Bast, Robert C., primary, Hanash, Sam, primary, and Fahrmann, Johannes F., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figure from A Blood-Based Metabolite Panel for Distinguishing Ovarian Cancer from Benign Pelvic Masses

Author

Irajizad, Ehsan, primary, Han, Chae Y., primary, Celestino, Joseph, primary, Wu, Ranran, primary, Murage, Eunice, primary, Spencer, Rachelle, primary, Dennison, Jennifer B., primary, Vykoukal, Jody, primary, Long, James P., primary, Do, Kim Anh, primary, Drescher, Charles, primary, Lu, Karen, primary, Lu, Zhen, primary, Bast, Robert C., primary, Hanash, Sam, primary, and Fahrmann, Johannes F., primary

Published
2023
Full Text
View/download PDF

47. Supplementary data from Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability

Author

Yang, Hailing, primary, Mao, Weiqun, primary, Rodriguez-Aguayo, Cristian, primary, Mangala, Lingegowda S., primary, Bartholomeusz, Geoffrey, primary, Iles, Lakesla R., primary, Jennings, Nicholas B., primary, Ahmed, Ahmed Ashour, primary, Sood, Anil K., primary, Lopez-Berestein, Gabriel, primary, Lu, Zhen, primary, and Bast, Robert C., primary

Published
2023
Full Text
View/download PDF

48. Supplementary data from A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel

Author

Zhou, Jinhua, primary, Alfraidi, Albandri, primary, Zhang, Shu, primary, Santiago-O'Farrill, Janice M., primary, Yerramreddy Reddy, Venkata Krishna, primary, Alsaadi, Abdulkhaliq, primary, Ahmed, Ahmed A., primary, Yang, Hailing, primary, Liu, Jinsong, primary, Mao, Weiqun, primary, Wang, Yan, primary, Takemori, Hiroshi, primary, Vankayalapati, Hariprasad, primary, Lu, Zhen, primary, and Bast, Robert C., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Figure 1 from Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer

Author

Landen, Charles N., primary, Goodman, Blake, primary, Katre, Ashwini A., primary, Steg, Adam D., primary, Nick, Alpa M., primary, Stone, Rebecca L., primary, Miller, Lance D., primary, Mejia, Pablo Vivas, primary, Jennings, Nicolas B., primary, Gershenson, David M., primary, Bast, Robert C., primary, Coleman, Robert L., primary, Lopez-Berestein, Gabriel, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results